Table 3.
Meta-analysis of the effects of SOX2-OT overexpression on survival and clinical parameters.
| Outcome | No. of trials (patients) | HR or RR(95% CI) | P value of Fixed-effect Model | Z value of Fixed-effect Model | HR or RR(95% CI) | P value of Random-effect Model | Z value of Random-effect Model | Heterogeneity I2(%), P value | P value of Egger’s test, Begg’s test |
|---|---|---|---|---|---|---|---|---|---|
| Fixed-Effect estimate | Random-Effect estimate | ||||||||
| OS | 11 (1029) | 2.026 (1.691–2.428) | <0.0001 | 7.6500 | 2.026 (1.691–2.428) | <0.0001 | 7.6500 | 0.0%, 0.9698 | 0.0135, 0.0158 |
| DFS | 2 (241) | 2.332 (1.593–3.413) | <0.0001 | 4.3575 | 2.554 (1.261–5.174) | 0.0092 | 2.6045 | 66.6%, 0.0836 | NA, NA |
| Tumor stage (III/IV versus I/II) | 9 (784) | 1.526 (1.325–1.758) | <0.0001 | 5.8585 | 1.468 (1.106–1.949) | 0.0079 | 2.6566 | 71.9%, 0.0004 | 0.8772, 0.8348 |
| Lymphatic metastasis (yes versus no) | 7 (631) | 1.534 (1.311–1.794) | <0.0001 | 5.3453 | 1.554 (1.211–1.994) | 0.0005 | 3.4685 | 52.2%, 0.0508 | 0.4831, 0.8806 |
| Distant metastasis (yes versus no) | 4 (486) | 3.054 (1.866–4.999) | <0.0001 | 4.4415 | 2.957 (1.620–5.400) | 0.0004 | 3.5295 | 18.3%, 0.2989 | 0.1705, 0.1742 |
| Tumor size (large versus small) | 7 (667) | 1.285 (1.118–1.478) | 0.0004 | 3.5306 | 1.264 (1.019–1.566) | 0.0329 | 2.1336 | 56.2%, 0.0330 | 0.3387, 0.2931 |
| Depth of tumor invasion (T3/4 versus T1/2) | 3 (369) | 1.552 (1.274–1.890) | <0.0001 | 4.3703 | 1.557 (1.280–1.894) | <0.0001 | 4.4300 | 0.0%, 0.9288 | 0.5396, 0.6015 |
| Differentiation (poor/moderate versus well) | 9 (834) | 1.131 (0.978–1.309) | 0.0977 | 1.6560 | 1.122 (0.800–1.573) | 0.5062 | 0.6647 | 78.7%, <0.0001 | 0.5987, 0.2971 |
| Age (elder versus young) | 10 (929) | 0.981 (0.862–1.116) | 0.7661 | -0.2975 | 0.966 (0.821–1.138) | 0.6812 | -0.4108 | 31.4%, 0.1575 | 0.1080, 0.3970 |
| Gender (male versus female) | 8 (796) | 1.022 (0.921–1.134) | 0.6798 | 0.4128 | 1.013 (0.916–1.122) | 0.7959 | 0.2587 | 0.0%, 0.8005 | 0.5557, 0.3223 |
HR, hazard ratio; RR, relative risk; CI, confidence interval; OS, overall survival; DFS, disease-free survival; NA, not available.
I2, index for assessing heterogeneity; value ≥25% indicates a moderate to high heterogeneity.
Egger’s test: P value of Egger’s regression for asymmetry assessment.
Begg’s test: P value of Begg and Mazumdar rank correlation test for asymmetry assessment.
Bold italics indicate statistically significant values (P < 0.05).